{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:14:51Z","timestamp":1789514091578,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi del Piemonte Orientale Amedeo Avogrado"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Breast cancer (BC) is a leading public-health issue affecting women on a global scale. Thanks to the widespread implementation of screening programs and the improvement in therapies, women with BC live longer but they also are more likely to experience an increased risk of other diseases. Reasons for this increased risk include genetics, shared risk factors, and adverse effects from BC treatment. Therefore, this research aimed to analyse the risk of myocardial infarction (MI) and stroke in women with BC, considering the potential side effects of treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For the analysis, we used data coming from the Piedmont Longitudinal Study (PLS), an administrative cohort based on the record-linkage among census data and several health-administrative databases involving more than 4 million inhabitants. The study population comprised women aged 30\u201375\u00a0years from the PLS study, excluding those with myocardial infarction or stroke at baseline. To analyse the investigated associations, competing risk analyses were performed, through the Cause-Specific Proportional Hazards model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1,342,333 women ranging from 30 to 75\u00a0years old, 19,203 had a BC diagnosis, of whom 206 (1.1%) experienced a subsequent MI and 203 (1.1%) a stroke. Women with BC showed an increased risk for MI (HR: 1.20; 95% CI 1.05\u20131.38) and for stroke (HR: 1.58; 95% CI 1.38\u20131.82). Chemotherapy was observed to be the major risk factor for MI in BC women, while no different risk by therapy was found for stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results supported the hypothesis about the toxic effect of BC therapies, suggesting that clinicians should routinely and actively screen for treatment-related toxicities in women with BC and that researchers should prioritize personalized treatments to minimize potentially devastating side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-07900-0","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:46:58Z","timestamp":1769690818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of myocardial infarction and stroke after breast cancer: an analysis of a population of 1.3 million women from North-West Italy"],"prefix":"10.1007","volume":"215","author":[{"given":"Fulvio","family":"Ricceri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Favaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Winston","family":"Gilcrease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Claudia","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ferracin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Di Cuonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Macciotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Dansero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"d\u2019Errico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmauro","family":"Numico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gnavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Sacerdote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"7900_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-030-20301-6_4","volume":"1152","author":"M Fahad Ullah","year":"2019","unstructured":"Fahad Ullah M (2019) Breast cancer: current perspectives on the disease status. Adv Exp Med Biol 1152:51\u201364. https:\/\/doi.org\/10.1007\/978-3-030-20301-6_4","journal-title":"Adv Exp Med Biol"},{"key":"7900_CR2","unstructured":"Guidelines Breast Neoplasm 2018. https:\/\/www.aiom.it\/wp-content\/uploads\/2018\/11\/2018_LG_AIOM_Breast_ENversion.pdf"},{"key":"7900_CR3","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(05)66546-4","volume":"365","author":"U Veronesi","year":"2005","unstructured":"Veronesi U, Boyle P, Goldhirsch A et al (2005) Breast cancer. Lancet 365:1727\u20131741. https:\/\/doi.org\/10.1016\/S0140-6736(05)66546-4","journal-title":"Lancet"},{"key":"7900_CR4","unstructured":"Odle TG (2014) Adverse effects of breast cancer treatment. Radiol Technol 85:297M-319M; quiz 320M-323M"},{"key":"7900_CR5","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/S0140-6736(00)02277-7","volume":"355","author":"R Peto","year":"2000","unstructured":"Peto R, Boreham J, Clarke M et al (2000) UK and USA breast cancer deaths down 25% in year 2000 at ages 20\u201369 years. Lancet 355:1822. https:\/\/doi.org\/10.1016\/S0140-6736(00)02277-7","journal-title":"Lancet"},{"key":"7900_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.radonc.2016.08.017","volume":"121","author":"T Grantzau","year":"2016","unstructured":"Grantzau T, Overgaard J (2016) Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: a systematic review and meta-analysis of population-based studies including 522,739 patients. Radiother Oncol 121:402\u2013413. https:\/\/doi.org\/10.1016\/j.radonc.2016.08.017","journal-title":"Radiother Oncol"},{"key":"7900_CR7","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ijc.29462","volume":"137","author":"F Ricceri","year":"2015","unstructured":"Ricceri F, Fasanelli F, Giraudo MT et al (2015) Risk of second primary malignancies in women with breast cancer: results from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 137:940\u2013948. https:\/\/doi.org\/10.1002\/ijc.29462","journal-title":"Int J Cancer"},{"key":"7900_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987\u2013998. https:\/\/doi.org\/10.1056\/NEJMoa1209825","journal-title":"N Engl J Med"},{"key":"7900_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","volume":"80","author":"R Florido","year":"2022","unstructured":"Florido R, Daya NR, Ndumele CE et al (2022) Cardiovascular disease risk among cancer survivors: the atherosclerosis risk in communities (ARIC) study. J Am Coll Cardiol 80:22\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.042","journal-title":"J Am Coll Cardiol"},{"key":"7900_CR10","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43:4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"7900_CR11","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.mcna.2017.06.003","volume":"101","author":"N Gegechkori","year":"2017","unstructured":"Gegechkori N, Haines L, Lin JJ (2017) Long-term and latent side effects of specific cancer types. Med Clin North Am 101:1053\u20131073. https:\/\/doi.org\/10.1016\/j.mcna.2017.06.003","journal-title":"Med Clin North Am"},{"key":"7900_CR12","doi-asserted-by":"publisher","first-page":"7685","DOI":"10.1200\/JCO.2005.08.789","volume":"23","author":"JD Floyd","year":"2005","unstructured":"Floyd JD, Nguyen DT, Lobins RL et al (2005) Cardiotoxicity of cancer therapy. J Clin Oncol 23:7685\u20137696. https:\/\/doi.org\/10.1200\/JCO.2005.08.789","journal-title":"J Clin Oncol"},{"key":"7900_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","volume":"12","author":"MS Ewer","year":"2015","unstructured":"Ewer MS, Ewer SM (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12:547\u2013558. https:\/\/doi.org\/10.1038\/nrcardio.2015.65","journal-title":"Nat Rev Cardiol"},{"key":"7900_CR14","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","volume":"11","author":"ML Henry","year":"2018","unstructured":"Henry ML, Niu J, Zhang N et al (2018) Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast\u00a0cancer patients. JACC Cardiovasc Imaging 11:1084\u20131093. https:\/\/doi.org\/10.1016\/j.jcmg.2018.06.005","journal-title":"JACC Cardiovasc Imaging"},{"key":"7900_CR15","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1093\/eurheartj\/ehae637","volume":"45","author":"T L\u00f3pez-Fern\u00e1ndez","year":"2024","unstructured":"L\u00f3pez-Fern\u00e1ndez T, Marco I, Aznar MC et al (2024) Breast cancer and cardiovascular health. Eur Heart J 45:4366\u20134382. https:\/\/doi.org\/10.1093\/eurheartj\/ehae637","journal-title":"Eur Heart J"},{"key":"7900_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41416-024-02888-0","volume":"132","author":"GM Walls","year":"2025","unstructured":"Walls GM, Bergom C, Mitchell JD et al (2025) Cardiotoxicity following thoracic radiotherapy for lung cancer. Br J Cancer 132:311\u2013325. https:\/\/doi.org\/10.1038\/s41416-024-02888-0","journal-title":"Br J Cancer"},{"key":"7900_CR17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195\u20131205. https:\/\/doi.org\/10.1016\/S0140-6736(16)32616-2","journal-title":"Lancet"},{"key":"7900_CR18","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/ejhf.1758","volume":"22","author":"J Tromp","year":"2020","unstructured":"Tromp J, Boerman LM, Sama IE et al (2020) Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. Eur J Heart Fail 22:1239\u20131246. https:\/\/doi.org\/10.1002\/ejhf.1758","journal-title":"Eur J Heart Fail"},{"key":"7900_CR19","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/ijc.32908","volume":"147","author":"KE Henson","year":"2020","unstructured":"Henson KE, McGale P, Darby SC et al (2020) Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer: cohort study of 2 million women from 57 cancer registries in 22 countries. Int J Cancer 147:1437\u20131449. https:\/\/doi.org\/10.1002\/ijc.32908","journal-title":"Int J Cancer"},{"key":"7900_CR20","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/eurjpc\/zwad243","volume":"30","author":"A Galimzhanov","year":"2023","unstructured":"Galimzhanov A, Istanbuly S, Tun HN et al (2023) Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis. Eur J Prev Cardiol 30:2018\u20132031. https:\/\/doi.org\/10.1093\/eurjpc\/zwad243","journal-title":"Eur J Prev Cardiol"},{"key":"7900_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jclinepi.2007.05.017","volume":"61","author":"I Baldi","year":"2008","unstructured":"Baldi I, Vicari P, Di Cuonzo D et al (2008) A high positive predictive value algorithm using hospital administrative data identified incident cancer cases. J Clin Epidemiol 61:373\u2013379. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.05.017","journal-title":"J Clin Epidemiol"},{"key":"7900_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ypmed.2010.01.007","volume":"50","author":"T Spadea","year":"2010","unstructured":"Spadea T, Bellini S, Kunst A et al (2010) The impact of interventions to improve attendance in female cancer screening among lower socioeconomic groups: a review. Prev Med 50:159\u2013164. https:\/\/doi.org\/10.1016\/j.ypmed.2010.01.007","journal-title":"Prev Med"},{"key":"7900_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/aje\/kwr430","volume":"175","author":"S Guarrera","year":"2012","unstructured":"Guarrera S, Ricceri F, Polidoro S et al (2012) Association between total number of deaths, diabetes mellitus, incident cancers, and haplotypes in chromosomal region 8q24 in a prospective study. Am J Epidemiol 175:479\u2013487. https:\/\/doi.org\/10.1093\/aje\/kwr430","journal-title":"Am J Epidemiol"},{"key":"7900_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0710-1","volume":"20","author":"J Caron","year":"2018","unstructured":"Caron J, Nohria A (2018) Cardiac toxicity from breast cancer treatment: Can we avoid this? Curr Oncol Rep 20:61. https:\/\/doi.org\/10.1007\/s11912-018-0710-1","journal-title":"Curr Oncol Rep"},{"key":"7900_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/postgradmedj-2016-134417","volume":"93","author":"TM Okwuosa","year":"2017","unstructured":"Okwuosa TM, Anzevino S, Rao R (2017) Cardiovascular disease in cancer survivors. Postgrad Med J 93:82\u201390. https:\/\/doi.org\/10.1136\/postgradmedj-2016-134417","journal-title":"Postgrad Med J"},{"key":"7900_CR26","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"key":"7900_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A et al (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31:63\u201375. https:\/\/doi.org\/10.1007\/s10557-016-6711-0","journal-title":"Cardiovasc Drugs Ther"},{"key":"7900_CR28","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1017\/S1047951117001536","volume":"27","author":"I Bini","year":"2017","unstructured":"Bini I, Asaftei SD, Riggi C et al (2017) Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma. Cardiol Young 27:1815\u20131822. https:\/\/doi.org\/10.1017\/S1047951117001536","journal-title":"Cardiol Young"},{"key":"7900_CR29","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/sj.bjc.6602562","volume":"92","author":"AM Geiger","year":"2005","unstructured":"Geiger AM, Chen W, Bernstein L (2005) Myocardial infarction risk and tamoxifen therapy for breast cancer. Br J Cancer 92:1614\u20131620. https:\/\/doi.org\/10.1038\/sj.bjc.6602562","journal-title":"Br J Cancer"},{"key":"7900_CR30","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/14740338.2016.1182493","volume":"15","author":"G Giordano","year":"2016","unstructured":"Giordano G, Spagnuolo A, Olivieri N et al (2016) Cancer drug related cardiotoxicity during breast cancer treatment. Expert Opin Drug Saf 15:1063\u20131074. https:\/\/doi.org\/10.1080\/14740338.2016.1182493","journal-title":"Expert Opin Drug Saf"},{"key":"7900_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.11838","volume":"2","author":"H Abdel-Qadir","year":"2019","unstructured":"Abdel-Qadir H, Thavendiranathan P, Fung K et al (2019) Association of early-stage breast cancer and subsequent chemotherapy with risk of atrial fibrillation. JAMA Netw Open 2:e1911838. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11838","journal-title":"JAMA Netw Open"},{"key":"7900_CR32","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1080\/10428190802140873","volume":"49","author":"S Myrehaug","year":"2008","unstructured":"Myrehaug S, Pintilie M, Tsang R et al (2008) Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 49:1486\u20131493. https:\/\/doi.org\/10.1080\/10428190802140873","journal-title":"Leuk Lymphoma"},{"key":"7900_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S1470-2045(05)70251-5","volume":"6","author":"SC Darby","year":"2005","unstructured":"Darby SC, McGale P, Taylor CW, Peto R (2005) Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6:557\u2013565. https:\/\/doi.org\/10.1016\/S1470-2045(05)70251-5","journal-title":"Lancet Oncol"},{"key":"7900_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/0929867013373994","volume":"8","author":"P Perego","year":"2001","unstructured":"Perego P, Corna E, De Cesare M et al (2001) Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem 8:31\u201337. https:\/\/doi.org\/10.2174\/0929867013373994","journal-title":"Curr Med Chem"},{"key":"7900_CR35","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/s0008-6363(98)00244-2","volume":"40","author":"PK Singal","year":"1998","unstructured":"Singal PK, Khaper N, Palace V, Kumar D (1998) The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 40:426\u2013432. https:\/\/doi.org\/10.1016\/s0008-6363(98)00244-2","journal-title":"Cardiovasc Res"},{"key":"7900_CR36","unstructured":"Arbuck SG, Christian MC, Fisherman JS, et al (1993) Clinical development of Taxol. J Natl Cancer Inst Monogr 11\u201324"},{"key":"7900_CR37","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.1991.9.9.1692","volume":"9","author":"EK Rowinsky","year":"1991","unstructured":"Rowinsky EK, Gilbert MR, McGuire WP et al (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692\u20131703. https:\/\/doi.org\/10.1200\/JCO.1991.9.9.1692","journal-title":"J Clin Oncol"},{"key":"7900_CR38","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.acvd.2016.09.001","volume":"109","author":"S Jacob","year":"2016","unstructured":"Jacob S, Ferri\u00e8res J (2016) Breast cancer radiotherapy: a case of double jeopardy. Arch Cardiovasc Dis 109:587\u2013590. https:\/\/doi.org\/10.1016\/j.acvd.2016.09.001","journal-title":"Arch Cardiovasc Dis"},{"key":"7900_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jjcc.2019.02.001","volume":"74","author":"DY Kim","year":"2019","unstructured":"Kim DY, Youn J-C, Park M-S et al (2019) Cardiovascular outcome of breast cancer patients with concomitant radiotherapy and chemotherapy: a 10-year multicenter cohort study. J Cardiol 74:175\u2013181. https:\/\/doi.org\/10.1016\/j.jjcc.2019.02.001","journal-title":"J Cardiol"},{"key":"7900_CR40","doi-asserted-by":"publisher","first-page":"576","DOI":"10.21037\/gs.2018.11.10","volume":"7","author":"J Boyages","year":"2018","unstructured":"Boyages J, Baker L (2018) Evolution of radiotherapy techniques in breast conservation treatment. Gland Surg 7:576\u2013595. https:\/\/doi.org\/10.21037\/gs.2018.11.10","journal-title":"Gland Surg"},{"key":"7900_CR41","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.5114\/amsad.2019.86749","volume":"4","author":"I Rethemiotaki","year":"2019","unstructured":"Rethemiotaki I, Rethemiotakis A (2019) Stroke and breast cancer in the United States during 2007\u20132017. Arch Med Sci Atheroscler Dis 4:e134\u2013e140. https:\/\/doi.org\/10.5114\/amsad.2019.86749","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"7900_CR42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.radonc.2021.01.010","volume":"157","author":"MLH Milo","year":"2021","unstructured":"Milo MLH, Thorsen LBJ, Johnsen SP et al (2021) Risk of coronary artery disease after adjuvant radiotherapy in 29,662 early breast cancer patients: a population-based Danish Breast Cancer Group study. Radiother Oncol 157:106\u2013113. https:\/\/doi.org\/10.1016\/j.radonc.2021.01.010","journal-title":"Radiother Oncol"},{"key":"7900_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006242.pub2","volume":"2014","author":"S Balduzzi","year":"2014","unstructured":"Balduzzi S, Mantarro S, Guarneri V et al (2014) Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2014:CD006242. https:\/\/doi.org\/10.1002\/14651858.CD006242.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"7900_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102967","volume":"151","author":"M Arenas","year":"2020","unstructured":"Arenas M, Selek U, Kaidar-Person O et al (2020) The 2018 assisi think tank meeting on breast cancer: international expert panel white paper. Crit Rev Oncol Hematol 151:102967. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102967","journal-title":"Crit Rev Oncol Hematol"},{"key":"7900_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1121-8","volume":"35","author":"P Franco","year":"2018","unstructured":"Franco P, Iorio GC, Bartoncini S et al (2018) De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients. Med Oncol 35:62. https:\/\/doi.org\/10.1007\/s12032-018-1121-8","journal-title":"Med Oncol"},{"key":"7900_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.784409","volume":"9","author":"A Agha","year":"2022","unstructured":"Agha A, Wang X, Wang M et al (2022) Long-term risk of death from heart disease among breast cancer patients. Front Cardiovasc Med 9:784409. https:\/\/doi.org\/10.3389\/fcvm.2022.784409","journal-title":"Front Cardiovasc Med"},{"key":"7900_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021686","volume":"10","author":"E Belzile-Dugas","year":"2021","unstructured":"Belzile-Dugas E, Eisenberg MJ (2021) Radiation-induced cardiovascular disease: review of an underrecognized pathology. J Am Heart Assoc 10:e021686. https:\/\/doi.org\/10.1161\/JAHA.121.021686","journal-title":"J Am Heart Assoc"},{"key":"7900_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clbc.2016.07.003","volume":"17","author":"J Foglietta","year":"2017","unstructured":"Foglietta J, Inno A, de Iuliis F et al (2017) Cardiotoxicity of aromatase inhibitors in breast cancer patients. Clin Breast Cancer 17:11\u201317. https:\/\/doi.org\/10.1016\/j.clbc.2016.07.003","journal-title":"Clin Breast Cancer"},{"key":"7900_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2016.08.022","volume":"68","author":"H Abdel-Qadir","year":"2016","unstructured":"Abdel-Qadir H, Amir E, Fischer HD et al (2016) The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. Eur J Cancer 68:11\u201321. https:\/\/doi.org\/10.1016\/j.ejca.2016.08.022","journal-title":"Eur J Cancer"},{"key":"7900_CR50","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cjca.2021.02.009","volume":"37","author":"KK Teo","year":"2021","unstructured":"Teo KK, Rafiq T (2021) Cardiovascular risk factors and prevention: a perspective from developing countries. Can J Cardiol 37:733\u2013743. https:\/\/doi.org\/10.1016\/j.cjca.2021.02.009","journal-title":"Can J Cardiol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07900-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:28:56Z","timestamp":1770802136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07900-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7900"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07900-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All analyses were conducted according to the World Medical Association\u2019s Declaration of Helsinki. The Piedmont Longitudinal Study is included in the National Statistical Plan and does not need approval by the ethics committee. The EPIC study was approved by the Institutional Ethics Committee of \u201cAzienda Sanitaria\u201d of Florence (protocol code 96\/01, date of approval: 17 July 2001).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"66"}}